Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with; Schistosoma mansoni; and; S. haematobium; and Lao adults infected with; Opisthorchis viverrini
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
4651561
Author(s)
Falcoz, C.; Guzy, S.; Kovač, J.; Meister, I.; Coulibaly, J.; Sayasone, S.; Wesche, D.; Lin, Y. W.; Keiser, J.
R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with; Schistosoma mansoni; and; S. haematobium; and Lao adults infected with; Opisthorchis viverrini
Journal
J Pharmacokinet Pharmacodyn
Volume
49
Number
3
Pages / Article-Number
293-310
Keywords
Opisthorchiasis; Pediatric; Population pharmacokinetics; Praziquantel; R-praziquantel; Schistosomiasis
Mesh terms
Adult; Animals; Anthelmintics, therapeutic use; Child; Child, Preschool; Chromatography, Liquid; Humans; Laos; Opisthorchiasis, drug therapy; Opisthorchis, metabolism; Praziquantel, therapeutic use; Schistosoma mansoni, metabolism; Schistosomiasis, drug therapy; Tandem Mass Spectrometry
Abstract
Racemic praziquantel (PZQ) is the standard treatment for schistosomiasis and liver fluke infections (opisthorchiasis and clonorchiasis). The development of an optimal pediatric formulation and dose selection would benefit from a population pharmacokinetic (popPK) model. A popPK model was developed for R-PZQ, the active enantiomer of PZQ, in 664 subjects, 493 African children (2-15 years) infected with Schistosoma mansoni and S. haematobium, and 171 Lao adults (15-78 years) infected with Opisthorchis viverrini. Racemate tablets were administered as single doses of 20, 40 and 60 mg/kg in children and 30, 40 and 50 mg/kg in 129 adults, and as 3 x 25 mg/kg apart in 42 adults. Samples collected by the dried-blood-spot technique were assayed by LC-MS/MS. A two-compartment disposition model, with allometric scaling and dual first-order and transit absorption, was developed using Phoenix software. Inversely parallel functions of age described the apparent oral bioavailability (BA) and clearance maturation in children and ageing in adults. BA decreased slightly in children with dose increase, and by 35% in adults with multiple dosing. Crushing tablets for preschool-aged children increased the first-order absorption rate by 64%. The mean transit absorption time was 70% higher in children. A popPK model for R-PZQ integrated African children over 2 years of age with schistosomiasis and Lao adults with opisthorchiasis, and should be useful to support dose optimization in children. In vitro hepatic and intestinal metabolism data would help refining and validating the model in younger children as well as in target ethnic pediatric and adult groups.
